Melphalan

Generic Name
Melphalan
Brand Names
Alkeran, Evomela, Phelinun, Pepaxti
Drug Type
Small Molecule
Chemical Formula
C13H18Cl2N2O2
CAS Number
148-82-3
Unique Ingredient Identifier
Q41OR9510P
Background

Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.

Indication

Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.

Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.

Associated Conditions
Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

Low Dose Melphalan and Bortezomib for AML and High-Risk MDS

First Posted Date
2008-11-11
Last Posted Date
2018-10-24
Lead Sponsor
Dartmouth-Hitchcock Medical Center
Target Recruit Count
26
Registration Number
NCT00789256
Locations
🇺🇸

Integrated Community Oncology Network, Jacksonville, Florida, United States

🇺🇸

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma

First Posted Date
2008-11-04
Last Posted Date
2022-08-11
Lead Sponsor
Hackensack Meridian Health
Target Recruit Count
32
Registration Number
NCT00784823
Locations
🇺🇸

Hackensack University Medical Center, Hackensack, New Jersey, United States

High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy

First Posted Date
2008-09-05
Last Posted Date
2013-08-12
Lead Sponsor
Leeds Cancer Centre at St. James's University Hospital
Target Recruit Count
460
Registration Number
NCT00747877
Locations
🇬🇧

Raigmore Hospital, Inverness, Scotland, United Kingdom

🇬🇧

Ysbyty Gwynedd, Bangor, Wales, United Kingdom

🇬🇧

Glan Clwyd Hospital, Rhyl, Denbighshire, Wales, United Kingdom

and more 50 locations

Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma

Phase 1
Completed
Conditions
Multiple Myeloma
Interventions
Drug: Melphalan
Drug: Panobinostat
First Posted Date
2008-08-28
Last Posted Date
2014-05-08
Lead Sponsor
Oncotherapeutics
Target Recruit Count
40
Registration Number
NCT00743288
Locations
🇺🇸

James R. Berenson MD, Incorporated, West Hollywood, California, United States

🇺🇸

Comprehensive Blood and Cancer Center, Bakersfield, California, United States

🇺🇸

Rocky Mountain Cancer Centers - Denver Midtown, Denver, Colorado, United States

and more 1 locations

Bortezomib With Melphalan and Prednisone for Multiple Myeloma

First Posted Date
2008-08-14
Last Posted Date
2023-11-07
Lead Sponsor
Duke University
Target Recruit Count
45
Registration Number
NCT00734149
Locations
🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

First Posted Date
2008-07-29
Last Posted Date
2015-03-06
Lead Sponsor
SWOG Cancer Research Network
Registration Number
NCT00723658
Locations
🇺🇸

Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States

🇺🇸

St. Joseph Mercy Oakland, Pontiac, Michigan, United States

🇺🇸

Sparrow Regional Cancer Center, Lansing, Michigan, United States

and more 26 locations

Donor Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

Phase 2
Conditions
Lymphoma
First Posted Date
2008-07-22
Last Posted Date
2013-08-02
Lead Sponsor
Cancer Research UK
Target Recruit Count
25
Registration Number
NCT00720447

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

First Posted Date
2008-07-16
Last Posted Date
2024-07-18
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
53
Registration Number
NCT00716066
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

🇺🇸

Swedish Medical Center-First Hill, Seattle, Washington, United States

🇺🇸

Colorado Blood Cancer Institute, Denver, Colorado, United States

Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma

First Posted Date
2008-06-11
Last Posted Date
2018-07-06
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
122
Registration Number
NCT00695409
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Autologous Stem Cell Transplantation for Crohn's Disease

First Posted Date
2008-06-06
Last Posted Date
2024-02-14
Lead Sponsor
Paul Szabolcs
Target Recruit Count
20
Registration Number
NCT00692939
Locations
🇺🇸

UPMC Prebyterian- Adult Gastroenterology, Pittsburgh, Pennsylvania, United States

🇺🇸

Children's Hospital of Pittsburgh of UPMC-Bone Marrow Team, Pittsburgh, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy